Second-generation antipsychotics and metabolic disorders
| Author : Pierre Allain
||Date : 2010-1-24
The second-generation antipsychotics in particular olanzapine, are known to induce metabolic disorders, weight gain, hyperglycemia, hyperlipidemia. In 2003, the FDA and other American authorities had recommended to measure blood glucose and lipids before prescribing an second-generation antipsychotic
A study published in Archives of General Psychiatry of January 2010 shows that the percentage of measurements of glucose and lipids before olanzapine prescription did not increase after the recommendations, but the prescriptions of olanzapine fell whereas that of aripiprazole which has less metabolic adverse effects increased. This change has probably reasons other than the FDA guidelines.
Other information on antipsychotics.